Patent · US Active

Substituted imidazole compounds as KSP inhibitors

US7626040B2 · kind B2 · utility

1Cited by

0References

23Claims

0Family size

Assignee

Novartis Vaccines and Diagnostics, Inc. · US

Inventors

Paul A. Barsanti · Emeryville, US
Yi Xia · South San Francisco, US
Weibo Wang · Moraga, US
Kris Mendenhall · Concord, US
Liana Lagniton · Berkeley, US
Savithri Ramurthy · Walnut Creek, US
Megan C. Phillips · Lake Orion, US
Sharadha Subramanian · San Ramon, US
Rustum Boyce · San Francisco, US
Nathan Brammeier · Walnut Creek, US
Ryan Constantine · Oakland, US
David Duhl · Newington, US
Annette Walter · Mill Valley, US
Tinya Abrams · Richmond, US
Paul A. Renhowe · Danville, US

Key dates

Filing date	Aug 9, 2006
Grant date	Dec 1, 2009
Priority date	—
Expiry date	Nov 2, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.